(Q38167828)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Clive Page

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Mario Cazzola

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Maria Gabriella Matera

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

3 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

129-137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295085%20AND%20SRC:MED&resulttype=core&format=json

Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Clinical pharmacokinetics of salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Metabolism and pharmacokinetics of indacaterol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Metabolic considerations of drugs in the treatment of allergic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Indacaterol for chronic obstructive pulmonary disease (COPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723

Safety of indacaterol in the treatment of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.865723